Lipid-lowering agent: Difference between revisions
No edit summary |
No edit summary |
||
| (7 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
<languages /> | <languages /> | ||
<translate> | <translate> | ||
<!--T:1--> | |||
{{Drug List/ja}} | |||
{{PathNav|Medication|frame=1}} | |||
{| class="wikitable sortable" style="width:100%" | |||
|+脂質降下薬（その他） | |||
|- | |||
!一般名 | |||
!先発名 | |||
!class="unsortable"| 日本 | |||
!創薬/開発 | |||
!備考 | |||
|- | |||
|[[Omega-3 acid ethyl esters/ja]] | |||
|[https://www.takedamed.com/medicine/detail?medicine_id=601 ロトリガ](武田薬品) ([https://pins.japic.or.jp/pdf/newPINS/00060775.pdf PI]) ([https://www.takedamed.com/medicine/detail?medicine_id=601&setpopflage=true IF]) | |||
|販売 | |||
|[[Takeda Pharmaceutical Company]] | |||
| | |||
|- | |||
|[[Ethyl eicosapentaenoic acid/ja]] | |||
|[https://med.mochida.co.jp/medicaldomain/circulatory/epadel/index.html エパデール](持田製薬) ([https://med.mochida.co.jp/txt/pdf/epa-s_n22.pdf PI]) ([https://med.mochida.co.jp/interview/epas_n22.pdf IF]) | |||
|販売 | |||
|[[Mochida Pharmaceutical]] | |||
| | |||
|- | |||
|} | |||
'''Lipid-lowering agents''', also sometimes referred to as '''hypolipidemic agents''', '''cholesterol-lowering drugs''', or '''antihyperlipidemic agents''' are a diverse group of [[pharmacology|pharmaceuticals]] that are used to lower the level of lipids and lipoproteins such as cholesterol, in the blood ([[hyperlipidemia]]). The American Heart Association recommends the descriptor 'lipid lowering agent' be used for this class of drugs rather than the term 'hypolipidemic'. | '''Lipid-lowering agents''', also sometimes referred to as '''hypolipidemic agents''', '''cholesterol-lowering drugs''', or '''antihyperlipidemic agents''' are a diverse group of [[pharmacology|pharmaceuticals]] that are used to lower the level of lipids and lipoproteins such as cholesterol, in the blood ([[hyperlipidemia]]). The American Heart Association recommends the descriptor 'lipid lowering agent' be used for this class of drugs rather than the term 'hypolipidemic'. | ||
== Classes == | == Classes == <!--T:2--> | ||
<!--T:3--> | |||
The several classes of lipid lowering drugs may differ in both their impact on the cholesterol profile and adverse effects. For example, some may lower [[low density lipoprotein]] (LDL) levels more so than others, while others may preferentially increase [[high density lipoprotein]] (HDL). Clinically, the choice of an agent depends on the patient's [[cholesterol|cholesterol profile]], [https://web.archive.org/web/20060511202743/http://hp2010.nhlbihin.net/atpiii/calculator.asp?usertype=prof cardiovascular risk], and the [[Liver function test|liver]] and [[Creatinine clearance|kidney]] functions of the patient, evaluated against the balancing of risks and benefits of the medications. In the United States, this is guided by the [[evidence-based medicine|evidence-based]] guideline most recently updated in 2018 by the [[American College of Cardiology]] & [[American Heart Association]]. | The several classes of lipid lowering drugs may differ in both their impact on the cholesterol profile and adverse effects. For example, some may lower [[low density lipoprotein]] (LDL) levels more so than others, while others may preferentially increase [[high density lipoprotein]] (HDL). Clinically, the choice of an agent depends on the patient's [[cholesterol|cholesterol profile]], [https://web.archive.org/web/20060511202743/http://hp2010.nhlbihin.net/atpiii/calculator.asp?usertype=prof cardiovascular risk], and the [[Liver function test|liver]] and [[Creatinine clearance|kidney]] functions of the patient, evaluated against the balancing of risks and benefits of the medications. In the United States, this is guided by the [[evidence-based medicine|evidence-based]] guideline most recently updated in 2018 by the [[American College of Cardiology]] & [[American Heart Association]]. | ||
<!--T:4--> | |||
===Established=== | ===Established=== | ||
* [[Statin]]s (HMG-CoA reductase inhibitors) are particularly well suited for lowering LDL, the cholesterol with the strongest links to vascular diseases. In studies using standard doses, statins have been found to lower LDL-C by 18% to 55%, depending on the specific statin being used. A risk exists of muscle damage ([[myopathy]] and [[rhabdomyolysis]]) with statins. Hypercholesterolemia is not a risk factor for mortality in persons older than 70 years and risks from statin drugs are more increased after age 85. | * [[Statin]]s (HMG-CoA reductase inhibitors) are particularly well suited for lowering LDL, the cholesterol with the strongest links to vascular diseases. In studies using standard doses, statins have been found to lower LDL-C by 18% to 55%, depending on the specific statin being used. A risk exists of muscle damage ([[myopathy]] and [[rhabdomyolysis]]) with statins. Hypercholesterolemia is not a risk factor for mortality in persons older than 70 years and risks from statin drugs are more increased after age 85. | ||
| Line 17: | Line 44: | ||
* [[Probucol]] (withdrawn in several countries) | * [[Probucol]] (withdrawn in several countries) | ||
=== Alternative === | === Alternative === <!--T:5--> | ||
<!--T:6--> | |||
* [[Lecithin]] has been shown to effectively decrease cholesterol concentration by 33%, lower LDL by 38% and increase HDL by 46%. | * [[Lecithin]] has been shown to effectively decrease cholesterol concentration by 33%, lower LDL by 38% and increase HDL by 46%. | ||
* [[Phytosterol]]s may be found naturally in plants. Similar to ezetimibe, phytosterols reduce the absorption of cholesterol in the gut, so they are most effective when consumed with meals. However, their precise mechanism of action differs from ezetimibe. | * [[Phytosterol]]s may be found naturally in plants. Similar to ezetimibe, phytosterols reduce the absorption of cholesterol in the gut, so they are most effective when consumed with meals. However, their precise mechanism of action differs from ezetimibe. | ||
| Line 30: | Line 58: | ||
* [[Flaxseed oil]] | * [[Flaxseed oil]] | ||
<!--T:7--> | |||
==Research== | ==Research== | ||
Investigational classes of hypolipidemic agents: | Investigational classes of hypolipidemic agents: | ||
| Line 39: | Line 68: | ||
* [[Bempedoic acid]], an ATP citrate lyase inhibitor | * [[Bempedoic acid]], an ATP citrate lyase inhibitor | ||
<!--T:8--> | |||
==See also== | ==See also== | ||
* [[ATC code C10]] | * [[ATC code C10]] | ||
<!--T:9--> | |||
{{Major Drug Groups}} | {{Major Drug Groups}} | ||
{{Lipid modifying agents}} | {{Lipid modifying agents}} | ||
<!--T:10--> | |||
{{二次利用|date=19 February 2024}} | {{二次利用|date=19 February 2024}} | ||
[[Category:Hypolipidemic agents]] | [[Category:Hypolipidemic agents]] | ||
</translate> | </translate> | ||